ストックスクリーナーアプリを入手
12.18
0.98%
-0.12
アフターアワーズ：
12.18
Mink Therapeutics Inc (INKT) 最新ニュース
Live MiNK Therapeutics, Inc. (INKT) Technical Analysis - Traders Union
Jennifer S. Buell to Discuss Clinical Development in LATAM – MiNK Therapeutics - Oncodaily
Understanding Momentum Shifts in (INKT) - Stock Traders Daily
Why (INKT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
INKT Q2 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Pre-Revenue Pipeline InvestmentEPS Surprise History - careplusvn.com
MiNK Therapeutics (INKT) insider reports stock trades - Stock Titan
Insider at MiNK Therapeutics (NASDAQ: INKT) reports stock transactions - Stock Titan
Mink Therapeutics, Inc. (INKT) Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MiNK Therapeutics (INKT) Drops 6.1% to $11.06 on Biotech Sector WeaknessLong Setup Ideas - dars.gov.et
MiNK (INKT) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Reported Period; After Earnings: Shares Move Lower 3.11% in Latest TradingProfit Inflection Point - dars.gov.et
MiNK Therapeutics Earnings Call Highlights ARDS Push - TipRanks
MiNK (INKT) Results Versus Estimates: EPS Does Not Reach the Reported Estimate for the Current Session; Trading Move: The Market Price Declines 3.11% for the Current SessionDividend Increase Stocks - careplusvn.com
MiNK (INKT) Move: Finishes 4.99% Higher at $12.20 in the Current Update; Next Test: the $11.59 to $12.81 Range Remains in Focus in the Latest SessionCalendar Spread Trade - siam.in
MiNK (INKT) Move: Moves 0.15% Up to $11.37 for the Current Session; Price Setup: Support at $10.80 and Resistance at $11.94 Frame the Range at the CloseAI Trade Signals - vinanet.vn
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.ca
Q3 EPS Estimate for MiNK Therapeutics Boosted by Analyst - MarketBeat
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - MarketBeat
INKT|Mink Therapeutics Inc|Price:11.680| - TradingKey
MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MiNK Therapeutics (INKT) Slides 5.17% as Biotech Stock Tests Key Support at $10.45AAII Neutral - vinanet.vn
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research SymposiumSlideshow - Seeking Alpha
MiNK Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
META_TITLE_QUOTE - Yahoo Finance
MiNK Therapeutics Q2 Earnings Call Highlights - MarketBeat
MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M - scanx.trade
INKT: Advanced phase II ARDS trial and global access for agenT-797, with stable financials - TradingView
MiNK Therapeutics (INKT.US) will release its earnings report after market close on August 13. - 富途牛牛
Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances - Investing.com
Transcript : MiNK Therapeutics, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
INKT: Phase II trial for agenT-797 in ARDS shows early promise; global access and financial discipline maintained - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - Investing News Network
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Australia
MiNK Therapeutics reports Phase 2 trial data for agenT-797 - Investing.com
MiNK Reports $3.1 Million Second-Quarter Loss and Phase 2 ARDS Update - Quiver Quantitative
MiNK Therapeutics Q2 loss narrows on expense discipline - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mink Therapeutics Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium - The Manila Times
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - Investing News Network
MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia - Blockonomi
Transactions récentes par des initiés de Mink Therapeutics Inc. R (6Q40.F) - Yahoo Finance France
Liquidity Mapping Around (INKT) Price Events - Stock Traders Daily
MiNK Therapeutics to Report Second Quarter 2026 Financial Results and Provide Corporate Update on agenT-797 Clinical Progress - Quiver Quantitative
MiNK Therapeutics to Report Second Quarter 2026 Financial - GlobeNewswire
New agenT-797 lung-injury data due from MiNK Aug. 13 - Stock Titan
MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday - MarketBeat
Mink Therapeutics to report Q2 results, host conference call and webcast - Bitget
INKT Q2'26 Earnings: revenue estimate is 0 USD - TradingView
MiNK Therapeutics (INKT) Climbs 5.7% as Biotech Momentum BuildsValue Area Low - dars.gov.et
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):